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Pendrin is a transmembrane chloride/anion exchanger highly expressed in thyroid, kidney, and
inner ear. Endoplasmic reticulum (ER)-retention of improperly folded Pendrin mutants is consid-
ered as the major cause for Pendred syndrome. However, the folding and degradation mechanisms
of Pendrin are poorly understood. Here, we report that treatment of 17-AAG, an Hsp90 inhibitor,
facilitates the folding of Pendrin through heat shock transcription factor 1 (Hsf1)-dependent induc-
tion of molecular chaperones. Furthermore, we demonstrate that Rma1, an E3 ubiquitin ligase local-
ized in the ER membrane, is involved in Pendrin degradation.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction plasm, and eventual degradation by the proteasome [12,13]. How-Pendrin is a transmembrane protein exchanging extracellular
Cl against intracellular monovalent anions such as I, HCO3,
OH, and formate in the apical region of thyroid folliculocytes, kid-
ney cortex, and inner ear [1–3]. Mutations in SLC26A4 gene encod-
ing Pendrin cause Pendred syndrome characterized by recessive
congenital hearing impairment, thyroid goiter, and partial defects
in iodide organiﬁcation [4,5]. Overall Pendred syndrome comprises
up to 10% of all congenital hearing impairments [6–8].
Retention of improperly folded Pendrin mutants in the endo-
plasmic reticulum (ER) has been suggested as the major patholog-
ical mechanism for Pendred syndrome [9,10]. Each Pendrin mutant
shows a different level of folding defect, which can be inferred by
its cellular localization, N-glycosylation level, and the degree of
folding-rescue by low temperature incubation [11]. Like other
transmembrane proteins, ER-retained misfolded Pendrin is
believed to be degraded by ER-associated degradation (ERAD),
which involves ubiquitylation, retro-translocation to the cyto-chemical Societies. Published by E
e conductance regulator; ER,
radation; Hsf1, heat shock
17-AAG, 17-allylamino-17-ever, the molecular details of folding and degradation of Pendrin
have not yet been investigated.
Here, we report that inhibition of Hsp90 activity by 17-AAG
(17-allylamino-17-demethoxygeldanamycin) treatment increases
the stability of Pendrin through Hsf1-dependent induction of
various molecular chaperones. In addition, ER-resident E3 ubiqui-
tin ligase Rma1 is shown to play an important role in Pendrin deg-
radation. However, cytosolic ubiquitin ligase CHIP seems to exert
little effect on Pendrin degradation. This is a ﬁrst study to under-
stand the roles of molecular chaperones and ubiquitin ligases in
folding and degradation of Pendrin, which might contribute to
developing strategies for curing Pendred syndrome.
2. Materials and methods
2.1. Plasmids
pCMV-Myc vectors containing cDNAs of Pendrin (SLC26A4) wild
type and mutants (M147V, L236P, and H723R) were kindly
provided by Dr. M.G. Lee (Yonsei University, College of Medicine,
Seoul, Korea) [11]. To generate plasmids containing Pendrin trun-
cation mutants, PCR-ampliﬁed Pendrin cDNA fragments (Pen-
drin1–166, Pendrin1–334, and Pendirn1–522), were cloned into the
XhoI and NotI sites of pCMV-Myc. Human Rma1 cDNA clones were
generated by RT-PCR using mRNA isolated from HEK293 cells. The
PCR products were cloned into the KpnI and NotI sites oflsevier B.V. All rights reserved.
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quence at the NheI site of pcDNA3.1 (Invitrogen).2.2. Cell culture and transfection
Human embryonic kidney 293 (HEK293) and HeLa cells were
maintained in DMEMmedium supplemented with 10% fetal bovine
serum and 1% penicillin–streptomycin. Plasmids or siRNA duplexes
were transfected into cells by using Lipofectamine2000 (Invitro-
gen). For siRNA, cells were transfected with 100 pmol of siRNA du-
plex targeted to Hsf1 (50-CAGGUUGUUCAUAGUCAGAAU-30), Rma1
(50-GCGACCUUCGAAUGUAAUA-30) and CHIP (50-UGCCGCCACUAU-
CUGUGUAAU-30). Scrambled siRNA duplex (Bioneer) was used as a
control.2.3. Immunoblotting
Harvested HEK293 and HeLa cells were lysed with a lysis buffer
containing 50 mM Tris–HCl (pH 7.4), 100 mM NaCl, 2 mM EDTA,
and 1% NP-40 supplemented with 1 mM PMSF, and 1/1000 prote-
ase inhibitor cocktail (Calbiochem) for 30 min at 4 C. Following
SDS–PAGE, immunoblotting was performed by using antibodies
against Myc (Santa Cruz Biotechnology), Flag (Cell Signalling),
b-tubulin (Santa Cruz Biotechnology), Hsp70 (Stressgen), Hsf1
(Cell Signalling), CHIP (Cell Signalling), Rma1 (Santa Cruz Biotech-
nology), and the chemiluminescence signals were detected
and quantiﬁed by chemiluminescence image equipment
(Syngene).
2.4. Immunoﬂuorescence microscopy
HeLa cells expressing Myc-Pendrin wild type and H723R were
seeded into incubation chamber pretreated with poly D-lysine for
4 h. 24 h after transfection of the expression vectors, 50 nM of
17-AAG was treated using 0.25% DMSO as a control. After 24 h,
cells were ﬁxed by 4% paraformaldehyde for 20 min at 4 C, and
then 0.25% Triton X-100 was added into the ﬁxed cells for antibody
permeability. Primary antibody against Myc was incubated for 2 h
at 4 C, and then FITC-labeled secondary antibody was added. After
staining nucleus with DAPI for 1 min, cellular localizations of
FITC-labeled Myc-Pendrin were analyzed by confocal microscope
(Nikon, Eclipse TE 300).ER Lumen
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Fig. 1. Schematic diagram of the putative topology of Pendrin. The putative topology of P
The mutation sites of Pendrin M147V, L236P, and H723R are indicated as open circles, and
truncation mutants. STAS is a sulfate transporter and antisigma factor antagonist doma3. Results
3.1. Treatment of 17-AAG, an Hsp90 inhibitor, increases the stability of
Pendrin
One of the predicted topologies of Pendrin suggests 12 trans-
membrane domains with both N-terminal and C-terminal ends
facing cytosol, although it needs further experimental veriﬁcation
[8,14,15], and Pendrin has two N-glycosylation sites at Asn167
and Asn172 residues [16] (Fig. 1). As previously reported [11],
Myc-tagged Pendrin transiently expressed in HEK293 cells showed
at least three bands on SDS–PAGE, which are designated as A, B,
and C forms (Fig. 2A). The A form is predicted to be an unglycosy-
lated form of Pendrin. The B form is immaturely glycosylated Pen-
drin in the ER and the C form represents maturely glycosylated
Pendrin on the plasma membrane.
Hsp90 has been shown to play an important role in the folding
of cystic ﬁbrosis transmembrane conductance regulator (CFTR), a
Cl channel whose folding defects are implicated in cystic ﬁbrosis
[17]. Therefore, we asked whether Hsp90 is also involved in the
folding of Pendrin. To address this question, we investigated the ef-
fect of Hsp90 inhibitor, 17-AAG, on the steady state level of Pen-
drin protein. Pendrin was expected to be degraded by 17-AAG
treatment if Pendrin is a client protein of Hsp90 like CFTR. How-
ever, in contrast to our expectation, when HEK293 cells expressing
Myc-Pendrin were treated with 17-AAG for 24 h, the A and B
forms, but not C form, were stabilized in a dose dependent manner
(Fig. 2A and E). Induction of Hsp70 by 17-AAG was monitored as an
indicator of Hsf1 activation. Since Hsp90 inhibits Hsf1 transcrip-
tion factor, inhibition of Hsp90 activates Hsf1, which in turn leads
to the induction of Hsf1 target genes most of which encode molec-
ular chaperones. 17-AAG treatment did not affect the transcript le-
vel of Pendrin, which was detected by qRT-PCR (Supplementary
Fig. 1). Moreover, Myc-PP5 expressed from the same CMV pro-
moter-controlled expression vector did not show any change in
PP5 protein levels upon 17-AAG treatment (Supplementary
Fig. 2). Therefore, 17-AAG-dependent increase in the Pendrin pro-
tein levels seems not to be caused by the effect of 17-AAG on tran-
scription or translation of the Pendrin gene.
We also examined the effect of 17-AAG on three Pendrin mu-
tants (M147V, L236P, and H723R) which were shown to have dif-
ferent levels of folding defects [11]. Pendrin M147V and H723R
showed reduced levels of C forms compared with wild typeSTAS domain
R
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endrin is shown as previously reported [16]. N-glycosylation sites are denoted as ‘Y’.
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Fig. 2. Stabilization of Pendrin by 17-AAG in HEK293 cells. Myc-tagged Pendrin wild type (A) and mutants, M147V (B), L236P (C), and H723R (D) were transiently expressed
in HEK293 cells, and the indicated amount of 17-AAG was treated for 24 h after transfection. 0.25% DMSO was treated as a control. Expression levels of Myc-Pendrin, Hsp70,
and b-tubulin were detected by immunoblotting. A, B, and C indicate unglycosylated, immaturely glycosylated, and maturely glycosylated forms of Pendrin, respectively. (E)
The relative amounts of wild type and mutant Pendrin B forms, and wild type C form after treatment with 0.25% DMSO (gray bar) or 5 lM 17-AAG (black bar) were quantiﬁed
from three independent experiments. The quantiﬁcation values of Pendrin were normalized to b-tubulin. (F) Stabilization of Pendrin truncation mutants by 17-AAG.
Transfected cells were treated for 24 h with 5 lM 17-AAG or 0.25% DMSO as a control.
K. Lee et al. / FEBS Letters 586 (2012) 2535–2541 2537(Fig. 2B and D), and L236P, having the most severe folding defects,
did not generate any mature C form and showed higher level of A
form compared with wild type or other mutants (Fig. 2C). 17-AAG
treatment stabilized the A and B forms of Pendrin M147V and
H723R, but not L236P (Fig. 2B–E). Neither wild type nor the mu-
tants showed noticeable changes in the stability of C forms upon
17-AAG treatment. Therefore, Hsp90 inhibition might induce par-
tial folding-rescue of Pendrin proteins, and its effect seems to be
different depending on the folding status of Pendrin.
To map the speciﬁc regions of Pendrin where the stability is af-
fected by 17-AAG, Pendrin truncation mutants were generated andexpressed in HEK293 cells (Fig. 1). 17-AAG treatment stabilized all
these truncation mutants, indicating that 17-AAG affects Pendrin
stability from the early stage of Pendrin synthesis (Fig. 2F).
Since different cell types have different cellular environments
including the chaperone system [18], the effect of 17-AAG treat-
ment on Pendrin stability was also examined in human cervical
cancer cell line HeLa cells. Myc-tagged Pendrin, transiently ex-
pressed in HeLa cells, exhibited higher levels of C form than either
the A or B form, and 17-AAG treatment led to a prominent increase
in the C form (Fig. 3A). These results might be caused by higher
folding capacity of HeLa cells for Pendrin compared with HEK293
- -
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Fig. 4. Hsf1-dependent induction of molecular chaperones is responsible for
Pendrin stabilization upon 17-AAG treatment. HEK293 cells were co-transfected
with Myc-Pendrin expression vector and Hsf1 siRNA duplex. Scrambled siRNA was
used as a negative control (NC). After 24 h of transfection, cells were treated with
5 lM 17-AAG for 24 h and protein expression levels were analyzed by immuno-
blotting. The relative amounts of Hsf1 normalized to b-tubulin are indicated.
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from lower transfection efﬁciency of HeLa than HEK293 cells could
also possibly contribute to the efﬁcient folding of Pendrin in HeLa
cells.
We also examined the effects of 17-AAG on the folding of Pen-
drin mutants, M147V and H723R, in HeLa cells. 17-AAG treatment
not only stabilized the A and B forms of Pendrin H723R, but also
partly rescued this mutant to the mature C form (Fig. 3B). Whereas,
Pendrin M147V, having stronger folding defects than H723R, failed
to generate the C form from the increased pool of A and B forms
(Fig. 3B). Next, we tested whether the C form of Pendrin H723R in-
creased by 17-AAG treatment actually reﬂected the proteins
reached to the plasma membrane. Indirect immunoﬂuorescence
microscopy revealed that Pendrin wild type was localized in the
plasma membrane as well as distributed throughout the cytosol
as small aggregates (Fig. 3C). In contrast, Pendrin H723R was re-
tained in the perinuclear region in the form of aggregates, reﬂect-
ing the ER-retention of the misfolded mutant proteins (Fig. 3C). 17-
AAG treatment noticeably induced plasma membrane localization
of Pendrin H723R, whereas the membrane localization of wild type
Pendrin was not signiﬁcantly changed by 17-AAG (Fig. 3C). There-
fore, depending on cellular environment, 17-AAG treatment can
facilitate the folding and exit of Pendrin from the ER to generate
a maturely glycosylated form. These results suggest that the 17-
AAG-dependent increase in Pendrin stability might involve the
improvement of protein folding rather than the simple accumula-
tion of misfolded proteins by inhibiting their degradation.
3.2. Hsf1 mediates the 17-AAG-dependent stabilization of Pendrin
Since 17-AAG treatment seems to assist Pendrin folding, we
hypothesized that the 17-AAG effect might be mediated by the
induction of molecular chaperones through the activation of Hsf1
rather than by a direct effect of the reduced Hsp90 chaperoneA
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Fig. 3. Effect of 17-AAG on Pendrin stability in HeLa cells. (A) Myc-Pendrin was transien
treatment of the indicated amount of 17-AAG for 24 h. (B) 5 lM of 17-AAG was treated f
H723R. (C) Localizations of Myc-Pendrin wild type and H723R were detected by immun
(green). Nucleus was stained with DAPI (blue).activity. To test this possibility, we investigated the effect of Hsf1
depletion on the 17-AAG-dependent stabilization of Pendrin.
When HEK293 cells were co-transfected with Hsf1 siRNA and Pen-
drin expression vector, 17-AAG-dependent Pendrin stabilization
was diminished, concomitant with the reduction of Hsp70 induc-
tion (Fig. 4). Upon 17-AAG treatment, the Pendrin B form was sta-
bilized by only 1.5-fold in Hsf1 knockdown cells compared with a
stabilization by 2.5-fold in cells transfected with scrambled siRNA.
Therefore, the Hsf1-dependent induction of various molecular
chaperones might be mainly responsible for the Pendrin stabiliza-B
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C
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A
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tly expressed in HeLa cells and the expression levels of Pendrin were detected after
or 24 h to HeLa cells transfected with expression vectors for Myc-Pendrin M147V or
oﬂuorescence microscopy with or without the treatment of 50 nM 17-AAG for 24 h
K. Lee et al. / FEBS Letters 586 (2012) 2535–2541 2539tion by 17-AAG. To identify speciﬁc molecular chaperones respon-
sible for Pendrin stabilization, we selected the major molecular
chaperone Hsp70 and its Hsp40 cochaperones, Hdj1 and Hdj2 as
candidates among the known Hsf1 targets. However, overexpres-
sion of Hsp70, Hdj1, and Hdj2 alone or in combination did not in-
duce signiﬁcant changes in Pendrin stability (data not shown).
Therefore, the 17-AAG effect might reﬂect coordinated actions of
multiple chaperones yet to be identiﬁed.
3.3. E3 ubiquitin ligase Rma1 is involved in Pendrin degradation
Misfolded Pendrin is believed to be degraded by ERAD, but E3
ubiquitin ligases mediating the process have not yet been identi-
ﬁed. Among the known E3 ubiquitin ligases involved in ERAD, we
ﬁrst examined whether Rma1 functions in Pendrin degradation.
Rma1, which forms ER membrane-associated ubiquitin ligase com-
plex with Ubc6e and Derlin-1, has been shown to promote prote-
asomal degradation of CFTR [19]. Overexpression of Rma1
reduced the steady state levels of Pendrin WT and H723R, but
not M147V and L236P (Fig. 5A and C). In addition, siRNA reduction
of Rma1 by around 49% slightly increased the amount of Pendrin
wild type B form, suggesting that Rma1 is involved in Pendrin deg-
radation (Fig. 5B and C). Pendrin mutants having higher folding de-
fects seem not to be susceptible to the changes in Rma1 levels
under our experimental conditions. To ﬁnd out speciﬁc regions of
Pendrin where Rma1 recognizes for degradation, we also investi-
gated the effect of Rma1 on the stability of Pendrin truncation mu-
tants. Overexpression of Rma1 decreased the protein levels of
Pendrin1–334 and Pendrin1–552 as well as wild type, but not Pen-H723R
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Fig. 5. Effect of Rma1 on Pendrin stability. (A and D) Flag-Rma1 was overexpressed with
were analyzed by immunoblotting. (B) Cellular Rma1 was depleted by Rma1 siRNA duple
mutants. After 24 h of further incubation, protein expression levels were detected by im
(C) The relative amounts of Pendrin WT B forms upon overexpression or depletion of
(unpaired Student’s t-test).drin1–166 (Fig. 5D). Therefore, Rma1 might recognize folding de-
fects after the synthesis of the third transmembrane domain
(Fig. 1).
Next, we investigated the role for CHIP in Pendrin degradation.
CHIP is a cytosolic E3 ubiquitin ligase which interacts with Hsp70/
Hsc70 and Hsp90 through its tetratricopeptide repeat (TPR) motifs,
and is also known to regulate CFTR degradation [19,20]. However,
neither overexpression nor depletion of CHIP signiﬁcantly changed
the steady state levels of Pendrin (Fig. 6A–C). Therefore, unlike
Rma1, CHIP might play little role in Pendrin degradation.
4. Discussion
It has been suggested that ER-retention of improperly folded
Pendrin is the major cause of Pendred syndrome. Although Pen-
dred disease comprises up to 10% of all congenital hearing deﬁcien-
cies, the folding and degradation mechanisms of Pendrin are
largely unknown. Our study is a ﬁrst attempt to elucidate the roles
of molecular chaperones and E3 ubiquitin ligases involved in Pen-
drin folding and degradation.
Initially, we used 17-AAG, an Hsp90 inhibitor, to test whether
Pendrin is a client protein of Hsp90 similar to CFTR. However, Pen-
drin was stabilized by 17-AAG treatment unlike typical Hsp90 cli-
ent proteins which are degraded upon Hsp90 inhibition. The
Pendrin-stabilization effect of 17-AAG was abolished by siRNA
reduction of Hsf1, indicating that induction of various molecular
chaperones is mainly responsible for the 17-AAG-dependent Pen-
drin stabilization. Since overexpression of Hsp70 and its Hsp40
cochaperones, Hdj1 and Hdj2, failed to deliver the stabilization ef-100 49 100 61otal Rma1 100 51 100 25
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Fig. 6. Effect of CHIP on Pendrin stability. (A) HEK293 cells were co-transfected
with expression vectors for Flag-CHIP and Myc-Pendrin for 24 h, and protein
expression levels were detected by immunoblotting. (B) Cellular CHIP was depleted
by siRNA for 24 h before the transfection of expression vector for Myc-Pendrin, and
then further incubated for 24 h to detect protein expression levels. The relative
amounts of CHIP normalized to b-tubulin are indicated. (C) The relative amounts of
Pendrin WT B forms upon overexpression or depletion of CHIP were quantiﬁed from
three independent experiments.
2540 K. Lee et al. / FEBS Letters 586 (2012) 2535–2541fect of Pendrin unlike the previous report demonstrating their roles
in CFTR stabilization [21], balanced actions of other chaperones
might be responsible for proper Pendrin folding.
Pendrin expressed in HeLa cells displayed higher levels of Pen-
drin folding and processing than that expressed in HEK293 cells,
possibly reﬂecting the differences in folding or cellular trafﬁcking
capacity of each cell type. Although 17-AAG could hardly rescue
the B form of wild type or mutant Pendrin to the C form in
HEK293 cells, 17-AAG could partially rescue the folding defects
of H723R mutant to generate the membrane-localized C form in
HeLa cells. These results demonstrate that Pendrin folding and traf-
ﬁcking to the plasma membrane can be altered by changes in the
cellular environment, and Hsp90 inhibitors can facilitate Pendrin
folding by optimizing the cellular folding capacity. Previously,
low temperature incubation, protein synthesis inhibitors, and
chemical chaperones were also shown to assist Pendrin folding
[11,13]. Although Hsp90 inhibitors are mainly considered as prom-
ising anti-cancer drugs targeting many oncogenic Hsp90 client
proteins, they also have a pharmacological potential to treat neuro-
degenerative diseases by acting as inducers of molecular chaper-
ones [22,23]. It has been shown that Hsp90 inhibitors can
alleviate neurodegenerative diseases such as Huntingtun’s disease,
tauopathy, and Parkinson’s disease by inhibiting protein aggrega-
tion [24–26]. Our results suggest that Hsp90 inhibitors might also
have a potential to be employed to cure Pendred syndrome.
We examined the roles for Rma1 and CHIP E3 ubiquitin ligases,
which have been known to degrade improperly folded CFTR, in
degradation of Pendrin [19,20]. Our Rma1 overexpression and siR-
NA experiments suggest that the ER-resident Rma1 may be in-
volved in Pendrin degradation by recognizing its folding defectsafter the synthesis of the third transmembrane domain. On the
other hand, it was difﬁcult to detect clear effect of CHIP on Pendrin
degradation. Compared with CFTR, Pendrin is predicted to have
smaller domains exposed to cytosol, which might be partly related
to the minor effects of the cytosolic ubiquitin ligase CHIP and cyto-
solic molecular chaperone Hsp90 on Pendrin stability.
In summary, we found that 17-AAG, an Hsp90 inhibitor, has a
therapeutic potential to rescue Pendrin folding defects through
the activation of Hsf1. The folding of Pendrin might be regulated
by the balanced actions of multiple components of chaperone sys-
tem and ERAD machinery, which are waiting for further investiga-
tion. Our study to understand the molecular mechanisms of
Pendrin folding and degradation would serve as a ﬁrst step to de-
velop curing strategies for Pendred syndrome.
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